10.1016/S0040-4020(01)96466-X
10.1016/S0040-4020(01)80873-5
Lin H., 1998, Zhongguo Haiyang Yaowu, 17, 1
10.1016/S0968-0896(00)00150-4
10.1002/(SICI)1098-1128(199909)19:5<388::AID-MED6>3.0.CO;2-H
Wender P. A., 2007, Drug Discovery Research: New Frontiers in the Post‐Genomic Era, 127
Pettit G. R., 1991, Progress in the Chemistry of Organic Natural Products, 154
Phase 1 clinical trials with bryostatin 1:
Weitman S., 1999, Clin. Cancer Res., 5, 2344
Phase 2 clinical studies:
10.1097/00008390-199912000-00010
Varterasian M. L., 2000, Clin. Cancer Res., 6, 825
Zonder J. A., 2001, Clin. Cancer. Res., 7, 38
10.1097/00001813-200208000-00001
Phase 1 and 2 trials of bryostatin 1 in combination with other drugs:
Dowlati A., 2003, Clin. Cancer Res., 9, 5929
10.1016/j.ygyno.2003.12.021
10.1158/1078-0432.CCR-05-2730
10.1007/s10637-006-6452-1
10.1158/1078-0432.CCR-06-1419
10.1007/s00280-008-0677-y
10.1007/s00280-009-0931-y
Papers on bryostatin 1 and its role in memory and learning and its possible usage for the treatment of Azheimer’s disease:
10.1016/j.ejphar.2008.02.014
10.1097/FBP.0b013e3282feb0d2
10.1016/j.tips.2006.12.002
10.1111/j.1527-3458.2006.00001.x
10.1016/j.ejphar.2005.02.028
For the total synthesis of bryostatin 7 see:
10.1016/S0040-4039(01)87348-2
10.1080/03086648508073398
For the total synthesis of bryostatin 2 see:
10.1002/(SICI)1521-3757(19980904)110:17<2507::AID-ANGE2507>3.0.CO;2-9
10.1002/(SICI)1521-3773(19980918)37:17<2354::AID-ANIE2354>3.0.CO;2-9
10.1016/S0040-4039(00)97711-6
10.1016/S0040-4039(00)95643-0
10.1016/0040-4039(96)00969-0
10.1016/S0040-4020(01)85588-5
10.1007/978-94-007-0797-9_3
For the first reported uses of glycosyl sulfones for CC bond formation see:
10.1016/S0040-4039(00)95048-2
10.1016/S0040-4039(00)95049-4
10.1016/S0040-4039(00)95050-0
10.1016/S0040-4020(01)87660-2
10.1016/S0040-4039(00)85190-4
10.1016/S0040-4039(00)60618-4
10.1016/0040-4039(96)00672-7
10.1016/S0040-4039(98)01955-8
10.1016/S0040-4039(99)02195-4
For the total synthesis of bryostatin 3 see:
10.1002/1521-3757(20000703)112:13<2376::AID-ANGE2376>3.0.CO;2-5
10.1002/1521-3773(20000703)39:13<2290::AID-ANIE2290>3.0.CO;2-6
10.1016/S0040-4039(98)01577-9
10.1016/0040-4039(95)01309-6
10.1016/0040-4039(95)01310-E
10.1016/S0040-4039(00)74063-9
For our group’s papers describing our enantiospecific formal total synthesis of the macrolide bryostatin 7 see:
10.1016/0040-4039(94)02477-S
K. J. Hale Abstracts of Papers of The American Chemical Society 2003 225 U311–U312 (Meeting Abstract: 195‐ORGN Lecture Title: Synthetic and biophysical studies on the bryostatin family of antitumor macrolides) 225th National Meeting of the American Chemical Society March 23–27 2003 New Orleans Louisiana USA.
10.1016/S0040-4020(00)01089-9
10.1016/S0040-4039(97)10500-7
10.1016/S0008-6215(00)84166-X
For other dithiane alkylation strategies for constructing the C(9)C(10) bond of the bryostatins see:
see also reference [24a].
10.1016/0040-4039(96)01759-5
10.1016/0957-4166(96)00380-1
10.1016/S0040-4039(00)94399-5
10.1016/0092-8674(95)90011-X
10.1093/oxfordjournals.jbchem.a124745
Otera J., 1986, Tetrahedron Lett., 27, 2382
10.1002/(SICI)1521-3757(19980803)110:15<2092::AID-ANGE2092>3.0.CO;2-M
10.1002/(SICI)1521-3773(19980817)37:15<1986::AID-ANIE1986>3.0.CO;2-Z
10.1016/j.tetlet.2006.01.097
10.1016/j.chembiol.2004.06.014
Keck G. E., 1998, Org. Synth., 77, 12
10.1016/j.tetlet.2006.09.094
10.1016/j.tet.2004.05.124
10.1002/1521-3757(20000901)112:17<3140::AID-ANGE3140>3.0.CO;2-G
10.1002/1521-3773(20000901)39:17<3012::AID-ANIE3012>3.0.CO;2-G
10.1002/1615-4169(200206)344:3/4<421::AID-ADSC421>3.0.CO;2-F
10.1016/j.tetlet.2004.09.124
10.1016/S0040-4039(02)01054-7
10.1016/S0040-4039(01)00841-3
10.1016/j.tetlet.2008.08.075
Green A. P., 2008, Synlett, 14, 2103
M. Frigerio PhD Thesis University of London 2003.